http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105030808-B
Outgoing Links
Predicate | Object |
---|---|
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 |
filingDate | 2008-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2018-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2018-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-105030808-B |
titleOfInvention | Micro-rna family of that modulates fibrosis and application thereof |
abstract | The present invention relates to micro-rna families of that modulates fibrosis and application thereof.In particular it relates to the identification as the micro-rna family for being referred to as miR-29a-c of the key regulators of fibrosis in heart tissue.Inventor show the member of miR-29 family in heart tissue response pressure and lower, and raised in the heart tissue of the mouse all resistant to pressure and fibrosis.The expression and active method of regulation miR-29miRNA family are additionally provided, as to fibrotic conditions, the treatment of related disease is lost including cardiomegaly, skeletal muscle fibre, other fibrillation related diseases and collagen. |
priorityDate | 2007-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2242.